Objectives: This retrospective study aims to evaluate off-label prescriptions and administrations of psychotropic medications in adolescents in a university psychiatric hospital in Switzerland. 
Introduction
The prescription of psychotropic drugs among children and adolescents in outpatient settings has increased over the past decades, according to studies performed in the United Kingdom (Hsia and Maclennan 2009) , United States (Olfson et al. 2012) , Canada (Meng et al. 2014) and Taiwan (Chien et al. 2013) . This growing practice is mainly due to the prescription of stimulants, atypical antipsychotics and selective serotonin reuptake inhibitors. In addition, high cross-national differences in the prevalence of psychotropic drugs prescription have been observed. For example, a comparative study performed in 2000 showed a prevalence of 6.7% in the United States, 2.9% in the Netherlands and 2.0% in Germany (Zito et al. 2008 ).
This high prescription rate raises concerns since a considerable number of these drugs are prescribed off-label. A nationwide survey conducted in Australia among general pediatricians and child and adolescent psychiatrists in 2000 found that 40% of psychotropic drugs were prescribed off-label (Efron et al. 2003) . A study performed among all child psychiatrists in the Netherlands in 2001 showed that for different psychiatric disorders, off-label prescribing varies from 19 to 71% (Hugtenburg et al. 2005) . In Germany, a retrospective cohort study revealed that 49% of antidepressants were prescribed off-label in [2004] [2005] [2006] (Dorks et al. 2013 ).
The notion of off-label refers to the use of a marketed drug in a situation that does not correspond to the terms explicitly recognized by the local authorities, such as Swissmedic in Switzerland or the Food and Drug Administration in the United States. In other terms, the therapeutic indication, the age, the dosage, the pharmaceutical form and/or the route of administration do not correspond to the official authorized use (Neubert et al. 2008 ). In the United States, according to the Committee on Drugs from the American Academy of Pediatrics, three-fourths of the prescribed medications lack pediatric use information (American Academy of Pediatrics 2002). Only few psychotropic drugs are authorized among this young population for treating mental illnesses such as schizophrenia or depression. In addition, despite that some atypical antipsychotics are approved to treat a range of conditions such as bipolar disorder and childhood schizophrenia, the majority of the pediatric population receiving these drugs are getting them for non-approved psychiatric conditions (Pathak et al. 2010) .
To improve the clinical study of drugs in pediatric patients, the FDA Modernization Act (1997), followed by the Best Pharmaceuticals for Children Act (2002) , incite drug companies to conduct 4/23 FDA-requested pediatric studies by granting an additional 6 months of marketing exclusivity.
The Pediatic Research Equity Act (2003) is a complementary program that authorizes the FDA to require the study of a new drug in pediatric populations (Bourgeois and Hwang 2017) . In the European Union, the pharmaceutical companies have to submit a Paediatric Investigation Plan since 2007, which aimed at ensuring that the necessary data are obtained through studies in children, with the reward of patent extension (European Medicines Agency 2017).
The active compounds approved for children and adolescent use can vary from one country to another according to its regulation policy. Only a few antipsychotics and antidepressants have pediatric indications in Switzerland (Table 1) . On the contrary, the most common benzodiazepines are approved in these patients (Swiss Drug Compendium).
The problem is more pronounced for hospitalized patients who received a higher number of psychotropic medications than in the community. Several studies conducted since 1976 have evaluated the prescription of these drugs in children and/or adolescents in psychiatric wards in the USA (Zito et al. 1994; Kaplan and Busner 1997; Safer 1997; Pappadopulos et al. 2002; Kelly et al. 2004; Lekhwani et al. 2004; Najjar et al. 2004; Pathak et al. 2004; Pogge et al. 2007; Meagher et al. 2013; Saldana et al. 2014) , Canada (Ahsanuddin et al. 1983; Procyshyn et al. 2014) , Finland (Sourander et al. 2002; Haapasalo-Pesu et al. 2004) , France (Winterfeld et al. 2008; Consoli et al. 2009 ), United Kingdom (Akram 2015) , Serbia (Pejovic-Milovancevic et al. 2011) , Israel (Gilat et al. 2011) , Australia (Dean et al. 2006) and China (Song and Guo 2013) . The proportion of patients treated with psychotropic medication was high, ranging from 30% to 100%. Despite the relative important number of studies, the majority have some limitations such as the evaluation of a single prevalence period (Ahsanuddin et al. 1983; Zito et al. 1994; Kaplan and Busner 1997; Pappadopulos et al. 2002; Sourander et al. 2002; Kelly et al. 2004; Lekhwani et al. 2004; Pathak et al. 2004; Dean et al. 2006; Pogge et al. 2007; Winterfeld et al. 2008; Consoli et al. 2009; Pejovic-Milovancevic et al. 2011; Procyshyn et al. 2014; Saldana et al. 2014; Akram 2015) , the analysis of prescriptions at a single point during hospitalization (Sourander et al. 2002; Haapasalo-Pesu et al. 2004) or at admission and/or discharge only (Safer 1997; Lekhwani et al. 2004; Gilat et al. 2011; Meagher et al. 2013; Procyshyn et al. 2014; Saldana et al. 2014; Akram 2015) , the study of antipsychotics only (Pappadopulos et al. 2002; Kelly et al. 2004; Pogge et al. 2007; Procyshyn et al. 2014; Saldana et al. 2014) , or the inclusion of children only (Lekhwani et al. 2004; Pathak et al. 2004; Akram 5/23 2015). The rate of off-label prescriptions was evaluated in only three of these studies, at a single prevalence period (Winterfeld et al. 2008; Procyshyn et al. 2014; Akram 2015) , at admission and discharge for antipsychotics (Procyshyn et al. 2014) , and at discharge for children (Akram 2015) .
To our knowledge, the present study is the first that focused on off-label prescription and administration of psychotropic drugs during the entire hospital stay of adolescents in a psychiatric ward during two separate periods (2008 and 2014) . All data presented in this study are based on the number of stays, that is, if a patient was hospitalized twice or more during the study period, each stay was considered independently as a new patient.
Methods

Study design and patients
Data extraction and analyses
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For both periods, data was extracted from the electronic prescription and administration databases. The demographic data collected included gender, age at admission, psychiatric diagnosis at discharge according to the International Statistical Classification of Diseases and Related Health Problems (ICD-10), as well as the number and duration of the hospitalizations for each patient within the study period. All prescribed and administrated psychotropic drugs were collected throughout the entire hospital stay of the patients, including the name of the active compound, the pharmaceutical form, the daily doses and the duration of the prescription and administration. As some drugs were prescribed as required (pro re nata or prn), a distinction was made between prescriptions and administrations. This was possible because all administrations actually performed by the nurses were recorded in the electronic database.
The number of different prescribers was also recorded. The Anatomical Therapeutic Chemical Classification (ATC) was used in order to characterize each drug class. All drugs that figured in the N05 (psycholeptic drugs) and N06
(psychoanaleptic drugs) classes were included in the extractions, including the phytomedicine.
Drugs from other classes that are usually used in psychiatry were also included, such as lamotrigine (N03AX09), valproate (N03AG01), biperiden (N04AA02) and nicotine (N07BA01).
For each patient and each psychotropic drug, the mean prescribed and administered daily dose was calculated.
The number of different drugs that were either prescribed or administered simultaneously in the same patient was also studied. Unlike the rest of the analyses where the pharmaceutical forms were separated, the analyses were made according to the active compound. The pharmaceutical forms were therefore regrouped. The results were expressed in terms of percentage of hospitalization days.
Off-label use
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All prescriptions and administrations were analyzed and categorized for off-label use according to the approved indications in Switzerland at the moment of the study (2008 and 2014, respectively) 44.7%, 39.5%, 13.2%, 1.3% and 1.3% in 2008, respectively, and 31.6%, 38.2%, 14.5%, 13.2%
and 2.6% in 2014, respectively.
Psychotropic drug prescriptions in 2008 and 2014
The proportion of patients with at least one psychotropic drug prescription was very high for both years: 94.7% in 96.1% in 2014, p=1.0 (Fig. 2 ) and the number of psychotropic drugs prescribed increased significantly from 2008 (n=224, mean 2.9 per patient) to 2014 (n=268, mean 3.5 per patient), p=0.02 for mean values (Table 3) .
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The main prescribed drugs for both years were antipsychotics: n=119 in (Table S1 ). For both years, the number of drugs administered was significantly lower than the number of drug The second therapeutic class of drugs with the highest rate of administration was anxiolytics 
Off-label prescriptions in 2008 and 2014
A high proportion of off-label prescriptions was observed, with 67.9% of all psychotropic drugs in 2008 and 67.5% in 2014, p=0.94 ( A very high proportion of patients (96.1% for both years) were prescribed at least 1 off-label psychotropic drug during their hospitalization (Fig. 4) . Up to 7 and 6 different off-label prescriptions were recorded in the same patient in 2008 and 2014, respectively.
Off-label administrations in 2008 and 2014
The rates of off-label administrations were similar to those of the off-label prescriptions, i.e. A high proportion of patients (78.9% for both years) were administered at least 1 off-label psychotropic drug during their stay (Fig. 4) . Up to 6 different off-label administrations were recorded in the same patient in 2008 and 2014.
Reasons for off-label prescriptions and administrations
The most frequent category of off-label use in 2008 was "Age + Diagnosis" (64 prescriptions, 57 administrations) followed by "Age" (59 prescriptions, 47 administrations), see Fig. 1 . In 2014, the most common category of off-label use was "Age" (69 prescriptions, 31 administrations) followed by "Diagnosis" (34 prescriptions, 29 administrations).
Discussion
This retrospective study, which should be considered as exploratory, showed a high prevalence of psychotropic drug prescriptions (around 95%) and administrations (around 78%) in adolescents in a Swiss psychiatric university hospital over the years 2008 and 2014.
Globally, the prevalence observed in our study is comparable to those observed in others studies performed in children and/or adolescents hospitalized in psychiatry (Ahsanuddin et al. 1983; Zito et al. 1994; Kaplan and Busner 1997; Safer 1997; Sourander et al. 2002; HaapasaloPesu et al. 2004; Lekhwani et al. 2004; Najjar et al. 2004; Pathak et al. 2004; Dean et al. 2006; Winterfeld et al. 2008; Consoli et al. 2009; Pejovic-Milovancevic et al. 2011; Meagher et al. 2013; Akram 2015) . However, large differences have been observed between these studies with a prevalence of psychotropic drug use ranging from 30-100%. These differences could be 13/23 explained by different factors such as the countries, the year of the studies, the type of hospital, the profile of the patients or the design of the studies.
In our study, the number of drugs prescribed simultaneously in the same patient increased between 2008 (mean 1.9) and 2014 (mean 2.8). However, the number of drugs administered simultaneously was lower and stable between the two study periods (mean (Winterfeld et al. 2008) . In both periods of our study, at least one off-label psychotropic prescription and administration was recorded in 96% and 79% of the patients, respectively. A lower prevalence was observed in the study of Winterfeld et al. where only 34% of the patients received one or more off-label psychotropic drugs (Winterfeld et al. 2008 ). Another study conducted in a children's psychiatric unit in United Kingdom from 1997 to 2012, found that on discharge only 25% of the patients were prescribed an unlicensed medicine or a licensed drug used in an unlicensed manner (Akram 2015) .
Antipsychotic use
The antipsychotics were the most frequently used drugs in this study. It is also important to notice the high proportion of antipsychotics that were prescribed off-label (92-94%), which highlights the need to evaluate the aspects of safety, risks and benefits. In pediatric patients hospitalized in psychiatry units in France, Winterfeld et al. found that 90% of antipsychotic drugs were prescribed off-label (Winterfeld et al. 2008) . In children and adolescents discharged from a tertiary care inpatient psychiatric facility in 2008-2009 in Canada, there were no Health Canada-approved indications for any of the second generation 15/23 antipsychotics prescribed at the time of the study. Based on the FDA indications, the rate of off-label prescribing was 90.5% at discharge (Procyshyn et al. 2014) . For the vast majority of the patients included in our study, adequate doses were prescribed and administered.
However, there were some exceptions such as haloperidol with the prescription of up 30 mg/day and administration of up to 21 mg/day, whereas the recommendation is at 0.5-10 mg/day for the treatment of mania in adolescents.
Antidepressant use
The In Switzerland, no antidepressant has been approved for the treatment of depression in patients under the age of 18 years. Some of them are indicated in the treatment of obsessive compulsive disorder (OCD) in children and adolescents (Table 1) . However, in our study, no patient had this diagnosis, which explains that we found a rate of off-label prescription of 100% to a recent network meta-analysis, fluoxetine was the only antidepressant statistically significantly more effective than placebo in children and adolescents with major depressive disorder (Cipriani et al. 2016) . Our results are in accordance with the study of Winterfeld et al., which found that 89% of the antidepressants were prescribed off-label (Winterfeld et al. 2008 ).
Anxiolytic and hypnotic use
The anxiolytic drugs come in second place after the antipsychotics in terms of prescription rate, with similar number of prescriptions between the two study periods. These drugs were mainly prescribed as prn medications, with only 58% and 45% of the prescriptions actually administered in 2008 and 2014, respectively. The percentages of off-label prescriptions (11-17%) are one of the lowest comparing to the rest of the psychotropic drugs. The explanation is that the majority of the anxiolytics prescribed are indicated in Switzerland for the treatment of anxiety in children and/or adolescent ( Table 1 ). The main reasons for off-label prescription were a dose higher than recommended or parenteral administration. In the study of Winterfeld et al., 28% of anxiolytics were prescribed off-label (Winterfeld et al. 2008) .
Regarding the use of the hypnotics, a substantial decrease in their prescription rate can be seen from 2008 to 2014. This decrease can be perceived as a good evolution since none of the hypnotics are currently recommended among the pediatric population (Table 1) .
Strengths and limitations
A strength of this study is that this is the first that recorded off-label use of psychotropic medications during the entire psychiatric hospital stay of adolescents at two separated time periods. Another strength is that, in order to have a more realistic and accurate idea of the use of off-label psychotropic medications in pediatric patients, both prescriptions and administrations were recorded. Indeed, some drugs were prescribed as required, which could lead to an overestimation of their use if they were not administered. In addition, some drugs prescribed on a regular basis could have not been administered if the patient refused the treatment, with is quiet common in psychiatry.
There are some limitations to this retrospective study, which should be considered as descriptive and exploratory. First, the differences of prescriptions between the two study periods could have been related to a change of prescribers with different individual habits, 17/23 rather than a real evolution of the practices in general. Indeed, the number of different prescribers was relatively low (7 in 2008 and 6 in 2014) , with only 2 common prescribers between the two periods. Secondly, it was not possible to know whether all drugs that were administered were actually validated by nurses in the electronic database and, inversely, if all drugs validated were actually administered; a slight over or under estimation of the real administration rates cannot therefore be totally excluded. Thirdly, although some differences were statistically significant between the two study periods, the results should be considered with caution, as the sample studied was relatively small. Furthermore, it is not possible to know if the prescription pattern observed reflects only local practices or if it could be extrapolated to other psychiatric hospitals in Switzerland or in Europe.
Conclusion
This retrospective study showed a high prevalence of psychotropic drug use in adolescents in a psychiatric university hospital in Switzerland. An increase in the number of prescriptions was observed between 2008 and 2014, but the number of administrations was stable.
Antipsychotics were the most frequently prescribed and administered drugs, followed by anxiolytics. In addition, a high proportion of these drugs were prescribed and administered offlabel according to the indications approved in Switzerland for both study periods. The therapeutic drug classes with the highest rate of off-label prescriptions and administrations were antidepressants, followed by antipsychotics.
Clinical Significance
A high proportion of off-label psychotropic drug use was observed in this study, despite a lack of proven efficacy for most drugs. These results highlight the need for new clinical trials in order to evaluate the risks and benefits of psychotropic medications in patients under the age of 18 years. At the same time, evaluating clinical practice patterns as well as engaging in the education of the clinicians concerning the known safety and efficacy of psychotropic drugs is an important factor to consider.
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